Hey Matt, So just a bit of weird data point. I got the J&J got Covid. I've got a lot of people in western in central mass with moderna and pfizer that are getting reinfected, all got our shots in that march-april timeframe. VERY light symptoms, i really didn't need to be out of work but my company has a 10 day policy and so does the state I live in (work out of state). I'm not sure where this all ends but with our vaccine rates in Mass I'm not real sure where this leaves us.
A nit: The chart you show does not show that "the vaccines produce antibodies 2-4 times higher" than previous infection. It shows that the *most effective* vaccines do. There are three other vaccines that are below "convalescent" on the chart.
To another point, if we ignore the error bars, increasing protection from 95% to 97% is actually pretty significant, since it decreases infections by 40%. In fact, as a policy matter, I'd say it's a pretty good bet that third doses for the elderly and other high-risk populations are going to be more useful than second doses for the "young and healthy" demographic.
Hey Matt, So just a bit of weird data point. I got the J&J got Covid. I've got a lot of people in western in central mass with moderna and pfizer that are getting reinfected, all got our shots in that march-april timeframe. VERY light symptoms, i really didn't need to be out of work but my company has a 10 day policy and so does the state I live in (work out of state). I'm not sure where this all ends but with our vaccine rates in Mass I'm not real sure where this leaves us.
A nit: The chart you show does not show that "the vaccines produce antibodies 2-4 times higher" than previous infection. It shows that the *most effective* vaccines do. There are three other vaccines that are below "convalescent" on the chart.
To another point, if we ignore the error bars, increasing protection from 95% to 97% is actually pretty significant, since it decreases infections by 40%. In fact, as a policy matter, I'd say it's a pretty good bet that third doses for the elderly and other high-risk populations are going to be more useful than second doses for the "young and healthy" demographic.